Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03446846 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy and Safety of MIN-117 in Adult Patients With Major Depressive Disorder
A Phase 2 study, sponsored by Minerva Neurosciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 360
- Enrollment target
NCT03446846 is a Phase 2 study that has completed, run by Minerva Neurosciences. The registered enrollment target is 360 participants.
The verdict
NCT03446846, a Phase 2 study, has completed, sponsored by Minerva Neurosciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 360 participants
- Enrollment target
Study Summary
MIN-117C03 is a 6-week, 3-arm, randomized, double-blind, placebo controlled study to investigate the safety and efficacy of MIN-117 in male and female patients with Major Depressive Disorder, aged 18 to 65 years. Approximately 324 patients were to be randomly assigned to 1 of 3 treatment arms, including placebo, 2.5 mg MIN-117, or 5.0 mg MIN-117, in a 2:1:1 ratio.
Interventions
- DRUG Placebo
- DRUG MIN-117 5.0 mg
- DRUG MIN-117 2.5 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 360 participants |
| Start Date | 2018-03-30 |
| Est. Completion | 2019-12-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03446846
The ClinicalTrials.gov registry entry for NCT03446846 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 360 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Minerva Neurosciences, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03446846 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03446846 about?
NCT03446846 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of MIN-117 in Adult Patients With Major Depressive Disorder". MIN-117C03 is a 6-week, 3-arm, randomized, double-blind, placebo controlled study to investigate the safety and efficacy of MIN-117 in male and female patients with Major Depressive Disorder, aged 18 to 65 years. Approximately 324 patients were to be randomly assigned to 1 of 3 treatment arms, inclu...
What is the current status of trial NCT03446846?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 360 participants. The study started on 2018-03-30. Estimated completion is 2019-12-13.
What interventions are being tested in trial NCT03446846?
The interventions under investigation include: Placebo (DRUG), MIN-117 5.0 mg (DRUG), MIN-117 2.5 mg (DRUG).
Who is sponsoring clinical trial NCT03446846?
This trial is sponsored by Minerva Neurosciences, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.